Advances in mechanism and management of adverse drug reactions targeting anti?angiogenesis drugs
10.3760/cma.j.issn.1008?6315.2019.05.022
- VernacularTitle:抗肿瘤血管生成靶向药物不良反应机制与处理进展
- Author:
Jianfang SHAO
1
;
Bin DONG
;
Qinghua ZHANG
Author Information
1. 辽宁省大连市药品不良反应监测中心 116021
- Keywords:
Targeted therapy of tumor;
Anti?angiogenie drugs;
Adverse reactions
- From:Clinical Medicine of China
2019;35(5):479-481
- CountryChina
- Language:Chinese
-
Abstract:
Angiogenesis plays an important role in the occurrence,development and metastasis of malignant tumors,and anti?angiogenesis has become an important therapeutic method in molecular targeted therapy of tumors.At present, the commonly used anti?angiogenesis drugs include monoclonal antibodies (bevacizumab),tyrosine kinase inhibitors (sorafenib,sunitinib),and endothelial cell growth inhibitors.The adverse reactions of different kinds of targeted anti?angiogenesis drugs are different.To grasp the mechanism of adverse reactions and the treatment measures of related adverse reactions of these drugs will improve the tolerance of patients receiving this kind of drugs, and at the same time, the prognosis of patients will be further improved.
